Pharming Presents Positive Phase II Topline Data For Leniolisib

By Reuters News

- Pharming Group N.V. PHAR.AS:

  • PRESENTS POSITIVE PHASE II TOPLINE DATA FOR LENIOLISIB IN GENETIC PIDS WITH IMMUNE DYSREGULATION AT ESID 2026

  • LENIOLISIB WELL-TOLERATED WITH BENEFITS IN IMMUNE DYSREGULATION MEASURES

  • MEAN SPLEEN VOLUME REDUCTION OF 26.4% IN PHASE II LENIOLISIB TRIAL

  • IMPROVEMENT IN LIVER STIFFNESS OBSERVED IN PHASE II LENIOLISIB TRIAL

  • MEAN LYMPH NODE LESION SIZE REDUCTION OF 33.7% IN PHASE II LENIOLISIB TRIAL

  • MEAN DLCO INCREASED BY 8.0% IN PHASE II LENIOLISIB TRIAL

  • ALL PHASE II LENIOLISIB STUDY COMPLETERS ENROLLED IN THREE-YEAR EXTENSION STUDY

  • LENIOLISIB WAS GENERALLY WELL-TOLERATED ACROSS ALL 4 GENOTYPES

  • TOPLINE RESULTS FROM SEPARATE PHASE II TRIAL IN CVID EXPECTED IN NOVEMBER

Further company coverage: PHAR.AS

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk